Abacor beats the best
Abacor to be more effective at lowering cholesterol than other
commercially available soy protein.
The soy composition Abacor is significantly more effective at lowering cholesterol than other commercially available soy protein, according to the ingredient's maker Norwegian firm NutriPharma.
The news is the result of a recent randomised, double-blind study conducted in Berlin by the German Institute for Food Research following a patent application by NutriPharma for its product.
The study investigated the effects of the patent-pending Abacor, a combination of soy proteins and soy phospholipids, and compared its effects on serum total, LDL and HDL cholesterol, triglycerides and apolipoprotein B with those of the best commercially available soy protein. The trial proved Abacor is significantly more effective in lowering serum lipids, according to NutriPharma.
The Norwegian company has been active mainly in the R&D of soy technology. It was recently awarded a patent covering the use of a soy composition in the prevention and treatment of cardiovascular and metabolic diseases.
Founded in 1993, Nutri Pharma says that its intellectual property includes over 1000 patent claims for composition, process and methods of use, all approved or applied for in the major international markets. It also makes the weight management products Nutrilett, Scan Diet and Nutriplan.
The company is now seeking industrial partners in the food and pharma sectors with international reach for its technologies.
